Table 2

Cancer staging and pathological features

Before matchingAfter matching
EA group
(n=449)
Non-EA group (n=2299)Standardised differenceEA group
(n=406)
Non-EA group (n=812)Standardised difference
AJCC stage0.71.8
 Stage I97 (21.6%)500 (21.7%)91 (22.4%)175 (21.6%)
 Stage II190 (42.3%)977 (42.5%)175 (43.1 %)374 (46.1%)
 IIA181 (40.3%)879 (38.2%)167 (41.1%)347 (42.7%)
 IIB6 (1.3%)74 (3.2%)5 (1.2%)15 (1.8%)
 IIC3 (0.7%)24 (1.0%)3 (0.7%)12 (1.5%)
 Stage III162 (36.1%)822 (35.8%)140 (34.5%)263 (32.4%)
 IIIA5 (1.1%)63 (2.7%)4 (1.0%)19 (2.3%)
 IIIB128 (28.5%)591 (25.7%)109 (26.8%)196 (24.1%)
 IIIC29 (6.5%)168 (7.3%)27 (6.7%)48 (5.9%)
Pathological features
 Tumour differentiation0.031.4
  Good36 (8.1%)174 (7.6%)33 (8.1%)64 (7.9%)
  Moderate379 (84.8%)1958 (85.7%)345 (85.0%)701 (86.3%)
  Poor32 (7.2%)153 (6.7%)28 (6.9%)47 (5.8%)
 Mucinous histology22 (4.9%)97 (4.3%)3.218 (4.4%)35 (4.3%)0.6
 Signet-ring histology15 (3.4%)61 (2.7%)4.113 (3.2%)20 (2.5%)4.5
 Lymphovascular invasion57 (12.8%)455 (19.9%)19.550 (12.3%)113 (13.9%)4.7
 Perineural invasion17 (3.8%)192 (8.4%)19.315 (3.7%)15 (1.8%)11.3
  • Values were counts (per cent). Categorical variables are analysed with Pearson χ2 tests.Standardised difference is the difference in mean, proportion or rank divided by the pooled SE, expressed as percentage.

  • AJCC, American Joint Committee on Cancer; EA, epidural analgesia.